Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

Inclusion criteria * Age ≥ 18 years. * Cisgender men who have sex with men. * Have taken oral TDF/FTC based PrEP during the past 6 months, either daily or on-demand, with a documented PrEP prescription. * Agreeing to be contacted personally by telephone (call, SMS) or e-mail. * Person affiliated with or a beneficiary of a social security scheme (article L1121-11 of the Public Health Code). * Informed and written consent, signed by the person and the investigator on the day of inclusion, at the latest, and before any examination carried out within the setting of the study (article L1122-1-1 of the Public Health Code). Non-inclusion criteria * Positive HIV test result at screening or enrollment visit, even if HIV infection is not confirmed. * Symptoms and/or clinical signs consistent with an acute HIV infection. * History of seizure disorder. * Ongoing Post-Exposure Prophylaxis (PEP) for HIV. * Last titer of hepatitis B surface antibody (anti-HBs) \< 10 mIU/mL. * Concomitant use of antimycobacterial (rifampin, rifapentine) or enzyme-inducing anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin, etc.). * Participants with severe hepatic impairment (Class C) as determined by Child-Pugh classification. * Participants having a non-treated chronic HCV infection. * Current or chronic history of liver disease or known hepatic or biliary abnormalities. * Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) \> 5-fold the upper normal limit (UNL). * …